Dry eye disease drug Xiidra is the centerpiece of the Bausch + Lomb acquisition. The deal with Novartis also includes two experimental products, one for eye pain and the other a medical device for delivering medicines to the eye.
Bausch + Lomb Broadens Eye Products Lineup Via $1.75B Deal With Novartis
